دورية أكاديمية
Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells.
| العنوان: | Interactions between Siglec-8 and endogenous sialylated cis ligands restrain cell death induction in human eosinophils and mast cells. |
|---|---|
| المؤلفون: | Cao Y; Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Rische CH; Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.; Department of Biomedical Engineering, Northwestern University McCormick School of Engineering, Evanston, IL, United States., Bochner BS; Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., O'Sullivan JA; Division of Allergy and Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2023 Oct 20; Vol. 14, pp. 1283370. Date of Electronic Publication: 2023 Oct 20 (Print Publication: 2023). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Eosinophils* , Mast Cells*, Humans ; Ligands ; Reactive Oxygen Species/metabolism ; Interleukin-5/metabolism ; Antigens, CD/metabolism ; Cell Death ; Sialic Acid Binding Immunoglobulin-like Lectins/metabolism ; Cytokines/metabolism |
| مستخلص: | Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is a sialoside-binding receptor expressed by eosinophils and mast cells that exhibits priming status- and cell type-dependent inhibitory activity. On eosinophils that have been primed with IL-5, GM-CSF, or IL-33, antibody ligation of Siglec-8 induces cell death through a pathway involving the β2 integrin-dependent generation of reactive oxygen species (ROS) via NADPH oxidase. In contrast, Siglec-8 engagement on mast cells inhibits cellular activation and mediator release but reportedly does not impact cell viability. The differences in responses between cytokine-primed and unprimed eosinophils, and between eosinophils and mast cells, to Siglec-8 ligation are not understood. We previously found that Siglec-8 binds to sialylated ligands present on the surface of the same cell (so-called cis ligands), preventing Siglec-8 ligand binding in trans. However, the functional relevance of these cis ligands has not been elucidated. We therefore explored the potential influence of cis ligands of Siglec-8 on both eosinophils and mast cells. De-sialylation using exogenous sialidase profoundly altered the consequences of Siglec-8 antibody engagement on both cell types, eliminating the need for cytokine priming of eosinophils to facilitate cell death and enabling Siglec-8-dependent mast cell death without impacting anti-Siglec-8 antibody binding. The cell death process licensed by de-sialylation resembled that characterized in IL-5-primed eosinophils, including CD11b upregulation, ROS production, and the activities of Syk, PI3K, and PLC. These results implicate cis ligands in restraining Siglec-8 function on eosinophils and mast cells and reveal a promising approach to the selective depletion of mast cells in patients with mast cell-mediated diseases. Competing Interests: Author BB receives remuneration for serving on the scientific advisory board of Allakos, Inc. and owns stock in Allakos. He has served as a consultant for GSK, Third Harmonic Bio, Lupagen, Acelyrin, and Sanofi/Regeneron, and receives publication-related royalty payments from Elsevier and UpToDate®. He is a co-inventor on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University during development and potential sales of such products. Author BB is also a co-founder of Allakos, which makes him subject to certain restrictions under University policy. The terms of this arrangement are being managed by Johns Hopkins University and Northwestern University in accordance with their conflict of interest policies. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2023 Cao, Rische, Bochner and O’Sullivan.) |
| References: | J Leukoc Biol. 2011 Aug;90(2):313-21. (PMID: 21551251) Eur Respir Rev. 2022 Jan 25;31(163):. (PMID: 35082127) J Biol Chem. 1997 Jan 10;272(2):1248-55. (PMID: 8995428) Front Immunol. 2022 Jan 28;13:833728. (PMID: 35154156) Proc Natl Acad Sci U S A. 2021 Apr 27;118(17):. (PMID: 33893239) J Biol Chem. 2000 Jan 14;275(2):861-6. (PMID: 10625619) Front Immunol. 2019 Mar 15;10:468. (PMID: 30930902) Mol Reprod Dev. 2014 Dec;81(12):1064-79. (PMID: 25359157) BMC Res Notes. 2020 Apr 10;13(1):211. (PMID: 32276656) Glycobiology. 2017 Jul 1;27(7):657-668. (PMID: 28369504) Biomed J. 2019 Aug;42(4):218-232. (PMID: 31627864) J Allergy Clin Immunol. 2019 Jun;143(6):2227-2237.e10. (PMID: 30543818) Blood. 2003 Jun 15;101(12):5014-20. (PMID: 12609831) Mol Cell Biol. 2006 Jul;26(13):4970-81. (PMID: 16782884) Biophys Rep (N Y). 2022 Jul 22;2(3):100064. (PMID: 36425332) Nat Commun. 2023 Apr 22;14(1):2327. (PMID: 37087495) Int Arch Allergy Immunol. 2019;180(2):91-102. (PMID: 31401630) J Histochem Cytochem. 1994 Nov;42(11):1417-25. (PMID: 7523489) Proc Natl Acad Sci U S A. 2016 Jul 19;113(29):E4170-9. (PMID: 27357658) Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7469-74. (PMID: 9636173) Mayo Clin Proc. 2021 Oct;96(10):2694-2707. (PMID: 34538424) Immunol Rev. 2018 Mar;282(1):151-167. (PMID: 29431215) Biochem Biophys Res Commun. 2018 Jan 1;495(1):854-859. (PMID: 29146181) J Allergy Clin Immunol. 2018 Jun;141(6):2196-2207. (PMID: 28888781) J Allergy Clin Immunol. 2022 Jun;149(6):1833-1844. (PMID: 35276243) J Immunol. 2006 Sep 1;177(5):2994-3003. (PMID: 16920935) J Biol Chem. 2005 Feb 11;280(6):4307-12. (PMID: 15563466) J Allergy Clin Immunol. 2000 Jun;105(6 Pt 1):1093-100. (PMID: 10856141) Am J Respir Cell Mol Biol. 2008 Jan;38(1):121-4. (PMID: 17690326) Front Immunol. 2021 Oct 11;12:737988. (PMID: 34721399) Front Immunol. 2019 Apr 04;10:699. (PMID: 31019513) Immunol Cell Biol. 2017 Apr;95(4):408-415. (PMID: 27874015) Blood. 1997 Aug 15;90(4):1345-64. (PMID: 9269751) Int J Biochem Cell Biol. 1999 Oct;31(10):1037-51. (PMID: 10582338) Cytokine. 2012 Jan;57(1):169-74. (PMID: 22079334) Glycobiology. 1999 Nov;9(11):1225-34. (PMID: 10536038) J Biol Chem. 1999 Aug 6;274(32):22729-38. (PMID: 10428856) J Allergy Clin Immunol. 2018 May;141(5):1774-1785.e7. (PMID: 28734845) Glia. 2020 May;68(5):989-998. (PMID: 31774586) Annu Rev Pathol. 2020 Jan 24;15:179-209. (PMID: 31977298) Anal Biochem. 1993 Jun;211(2):200-4. (PMID: 7686353) Front Immunol. 2018 Sep 20;9:2138. (PMID: 30294327) Blood. 2013 Mar 14;121(11):2084-94. (PMID: 23315163) Allergol Int. 2018 Sep;67S:S41-S44. (PMID: 29703694) Blood. 1995 Apr 15;85(8):2005-12. (PMID: 7718872) Cells. 2022 Mar 28;11(7):. (PMID: 35406705) Nat Chem Biol. 2005 Jul;1(2):93-7. (PMID: 16408005) J Immunol. 2014 Jun 1;192(11):5406-14. (PMID: 24790146) Glycobiology. 2023 Aug 14;33(7):532-544. (PMID: 37154567) Cells. 2021 May 20;10(5):. (PMID: 34065256) Elife. 2014 Sep 03;3:e04066. (PMID: 25187624) J Allergy Clin Immunol. 2008 Feb;121(2):499-505.e1. (PMID: 18036650) J Biol Chem. 2014 Jul 18;289(29):20370-6. (PMID: 24895121) Mucosal Immunol. 2021 Mar;14(2):366-376. (PMID: 32814824) J Biol Chem. 2000 Mar 24;275(12):8625-32. (PMID: 10722702) J Immunol Methods. 1989 Aug 15;122(1):97-103. (PMID: 2547875) JCI Insight. 2023 Mar 8;8(5):. (PMID: 36719745) Glycobiology. 2012 Jan;22(1):12-22. (PMID: 21725073) Nat Rev Immunol. 2022 May;22(5):294-308. (PMID: 34611316) FASEB J. 2001 Mar;15(3):645-58. (PMID: 11259383) J Pharmacol Exp Ther. 2009 Aug;330(2):608-12. (PMID: 19458105) |
| معلومات مُعتمدة: | P01 HL107151 United States HL NHLBI NIH HHS; U19 AI070535 United States AI NIAID NIH HHS; U19 AI136443 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: Siglec-8; cell death; cis ligand; eosinophil; mast cell; sialic acid |
| المشرفين على المادة: | 0 (Ligands) 0 (Reactive Oxygen Species) 0 (Interleukin-5) 0 (Antigens, CD) 0 (Sialic Acid Binding Immunoglobulin-like Lectins) 0 (Cytokines) |
| تواريخ الأحداث: | Date Created: 20231106 Date Completed: 20231107 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC10623328 |
| DOI: | 10.3389/fimmu.2023.1283370 |
| PMID: | 37928558 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2023.1283370 |